This is a long term study of patients with the clinical phenotype and genotype of neuronopathic Gaucher disease and their responses to therapy with a new biotherapeutic agent. This human enzyme, macrophage-targeted glucocerebrosidase, produced under the trade name Ceredase TM benefits patients without neurologic disease. It may prevent the onset of progression of neurologic disease.
Showing the most recent 10 out of 364 publications